We are a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Ex-US sub-licensees: commercialization and regulatory approval efforts outside the US
Indications
early-stage HER2-positive breast cancer (extended adjuvant)(Approved)
advanced/metastatic HER2-positive breast cancer(Approved)
Status note Marketed as NERLYNX: FDA-approved July 2017 for extended adjuvant treatment of early-stage HER2-overexpressed/amplified breast cancer following trastuzumab; February 2020 for advanced/metastatic HER2-positive breast cancer (with capecitabine); EC authorization 2018. Ongoing Phase 1 trial (NCT05372614, NCI-sponsored) of neratinib with fam-trastuzumab deruxtecan (ENHERTU).
Alisertib
Phase 2 · ActiveModality: small molecule (oral)
Target Aurora Kinase A
Partnerships Takeda: exclusive worldwide license for research, development and commercialization ($7M upfront October 2022; up to $287.3M milestones; tiered royalties)
Indications
extensive-stage small cell lung cancer (ALISCA-Lung1)(Phase 2)
breast cancer (ALISCA-Breast1)(Phase 2)
Status note Selective, reversible, ATP-competitive Aurora Kinase A inhibitor. ALISCA-Lung1 Phase 2 (monotherapy, extensive-stage SCLC) initiated February 2024; ALISCA-Breast1 Phase 2 initiated November 2024. Company intends to pursue alisertib initially in SCLC and hormone receptor-positive breast cancer.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 8 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.